Codiak’s exosomes give Sarepta’s AAVs a tissue-targeted invisibility cloak

Codiak is extending its exosome platform to AAVs by partnering with Sarepta to overcome two major obstacles for nucleic acid therapies: tissue-targeting and repeat dosing.

The resulting products would be vectors within vectors, with multiple AAVs encapsulated by human cell-derived exosomes that direct them to muscle tissues while hiding them from the immune system. Once inside cells,

Read the full 562 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE